Anesthetic pentobarbital inhibits proliferation and migration of malignant glioma cells

Cancer Letters

Volumn 282, Issue 1, 2009, Pages 35-42

  Xie, Jun ^a   Li, Yan ^a   Huang, Yijun ^a   Qiu, Pengxin ^a   Shu, Minfeng ^a   Zhu, Wenbo ^a   Ou, Yanqiu ^a   Yan, Guangmei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cell cycle; Malignant glioma; MAPK; Migration; Pentobarbital; Proliferation

Indexed keywords

ALPHA TUBULIN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PENTOBARBITAL; PROTEIN C JUN; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME INACTIVATION; GLIOBLASTOMA; GLIOMA CELL; MICROTUBULE ASSEMBLY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; BRAIN NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GLIOMA; HUMANS; HYPNOTICS AND SEDATIVES; MICROSCOPY, CONFOCAL; PENTOBARBITAL; RATS; WOUND HEALING;

EID: 67649392329     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.055     Document Type: Article

References (45)

1. DeAngelis L.M. Brain tumors. N. Engl. J. Med. 344 (2001) 114-123
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., and Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005) 987-996
3. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., and DePinho R.A. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15 (2001) 1311-1333
4. Giese A., Rief M.D., Loo M.A., and Berens M.E. Determinants of human astrocytoma migration. Cancer Res. 54 (1994) 3897-3904
5. Giese A., Bjerkvig R., Berens M.E., and Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21 (2003) 1624-1636
6. Louis D.N., Pomeroy S.L., and Cairncross J.G. Focus on central nervous system neoplasia. Cancer Cell 1 (2002) 125-128
7. Lefranc F., Brotchi J., and Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23 (2005) 2411-2422
8. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
9. Lopez-Munoz F., Ucha-Udabe R., and Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr. Dis. Treat. 1 (2005) 329-343
10. Naito M., Aoyama H., and Ito A. Inhibitory effect of phenobarbital on the development of gliomas in WF rats treated neonatally with N-ethyl-N-nitrosourea. J. Natl. Cancer Inst. 74 (1985) 725-728
11. Olson J.J., Friedman R., Orr K., Delaney T., and Oldfield E.H. Enhancement of the efficacy of x-irradiation by pentobarbital in a rodent brain-tumor model. J. Neurosurg. 72 (1990) 745-748
12. Olson J.J., Shelley C., Orr K., DeLaney T., and Oldfield E.H. The cerebral radioprotective effect of alternative barbiturates to pentobarbital. Neurosurgery 30 (1992) 720-723
13. Skolnick A. Primate study suggests pentobarbital may help protect the brain during radiation therapy. JAMA 264 (1990) 557-561
14. Kimler B.F., Liu C., Evans R.G., and Morantz R.A. Effect of pentobarbital on normal brain protection and on the response of 9L rat brain tumor to radiation therapy. J. Neurosurg. 79 (1993) 577-583
15. Li Y., Yin W., Wang X., Zhu W., Huang Y., and Yan G. Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. Proc. Natl. Acad. Sci. USA 104 (2007) 13438-13443
16. Renault-Mihara F., Beuvon F., Iturrioz X., Canton B., De Bouard S., Leonard N., Mouhamad S., Sharif A., Ramos J.W., Junier M.P., and Chneiweiss H. Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a protein kinase C delta-dependent mechanism. Mol. Biol. Cell 17 (2006) 5141-5152
17. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., and Poruchynsky M.S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272 (1997) 17118-17125
18. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zaharevitz D., Bollbuck B., Poy G., Sackett D., Nicolaou K.C., and Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA 97 (2000) 2904-2909
19. Lauffenburger D.A., and Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 84 (1996) 359-369
20. Strohmaier A.R., Porwol T., Acker H., and Spiess E. Three-dimensional organization of microtubules in tumor cells studied by confocal laser scanning microscopy and computer-assisted deconvolution and image reconstruction. Cells Tissues Organs 167 (2000) 1-8
21. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro. Oncol. 2 (2000) 45-59
22. Stupp R., Hegi M.E., Gilbert M.R., and Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J. Clin. Oncol. 25 (2007) 4127-4136
23. Wolff J.E., Berrak S., Koontz Webb S.E., and Zhang M. Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J. Neurooncol. 88 (2008) 57-63
24. Chang S.M., Prados M.D., Yung W.K., Fine H., Junck L., Greenberg H., Robins H.I., Mehta M., Fink K.L., Jaeckle K.A., Kuhn J., Hess K., and Schold C. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer 100 (2004) 1712-1716
25. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 100 (2000) 71-78
26. Olmsted J.B., and Borisy G.G. Microtubules. Annu. Rev. Biochem. 42 (1973) 507-540
27. Kroboth K., Newton I.P., Kita K., Dikovskaya D., Zumbrunn J., Waterman-Storer C.M., and Nathke I.S. Lack of adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in microtubule stability. Mol. Biol. Cell. 18 (2007) 910-918
28. Wen Y., Eng C.H., Schmoranzer J., Cabrera-Poch N., Morris E.J., Chen M., Wallar B.J., Alberts A.S., and Gundersen G.G. EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote cell migration. Nat. Cell Biol. 6 (2004) 820-830
29. Ballestrem C., Wehrle-Haller B., Hinz B., and Imhof B.A. Actin-dependent lamellipodia formation and microtubule-dependent tail retraction control-directed cell migration. Mol. Biol. Cell 11 (2000) 2999-3012
30. Rakic P., Knyihar-Csillik E., and Csillik B. Polarity of microtubule assemblies during neuronal cell migration. Proc. Natl. Acad. Sci. USA 93 (1996) 9218-9222
31. Terzis A.J., Thorsen F., Heese O., Visted T., Bjerkvig R., Dahl O., Arnold H., and Gundersen G. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br. J. Cancer 75 (1997) 1744-1752
32. Verma N.K., Dempsey E., Conroy J., Olwell P., McElligott A.M., Davies A.M., Kelleher D., Butini S., Campiani G., Williams D.C., Zisterer D.M., Lawler M., and Volkov Y. A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. J. Mol. Med. 86 (2008) 457-469
33. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
34. Beyer C.F., Zhang N., Hernandez R., Vitale D., Lucas J., Nguyen T., Discafani C., Ayral-Kaloustian S., and Gibbons J.J. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 68 (2008) 2292-2300
35. Failly M., Korur S., Egler V., Boulay J.L., Lino M.M., Imber R., and Merlo A. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol. Cancer Ther. 6 (2007) 773-781
36. Bacher G., Nickel B., Emig P., Vanhoefer U., Seeber S., Shandra A., Klenner T., and Beckers T. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. 61 (2001) 392-399
37. Ventilla M., and Brown W.J. The effect of barbiturates on microtubular assembly. J. Ultrastruct. Res. 54 (1976) 325-332
38. Edstrom A., Hansson H.A., Larsson H., and Wallin M. Effects of barbiturates on ultrastructure and polymerization of microtubules in vitro. Cell Tissue Res. 162 (1975) 35-47
39. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., and Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25 (2000) 55-57
40. Mischel P.S., and Cloughesy T.F. Targeted molecular therapy of GBM. Brain Pathol. 13 (2003) 52-61
41. Wong M.L., Kaye A.H., and Hovens C.M. Targeting malignant glioma survival signalling to improve clinical outcomes. J. Clin. Neurosci. 14 (2007) 301-308
42. Jussofie A., Reinhardt V., and Kalff R. GABA binding sites: their density, their affinity to muscimol and their behaviour against neuroactive steroids in human gliomas of different degrees of malignancy. J. Neural. Transm. Gen. Sect. 96 (1994) 233-241
43. Labrakakis C., Patt S., Hartmann J., and Kettenmann H. Functional GABA(A) receptors on human glioma cells. Eur. J. Neurosci. 10 (1998) 231-238
44. Hales T.G., and Tyndale R.F. Few cell lines with GABAA mRNAs have functional receptors. J. Neurosci. 14 (1994) 5429-5436
45. Hunter J., Thompson R.P., Rake M.O., and Williams R. Controlled trial of phetharbital, a non-hypnotic barbiturate, in unconugated hyperbilirubinaemia. Br. Med. J. 2 (1971) 497-499